Module

Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C

Source: Hepatitis Annual Update 2004

Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C

Program Director: John P. Phair, MD

Faculty:

Brent A. Tetri, MD

CREDIT INFORMATION

Release Date: September 10, 2004

Expiration Date: September 09, 2005

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the relationship between steatosis and hepatitis C virus (HCV) in terms of effect of obesity on the natural history of HCV liver disease, and the relationship between steatosis and treatment of hepatitis C, including weight-based dosing adjustments.
Discuss the relationship between diabetes and hepatitis C.
Define fatty liver syndromes.

Content includes:

Steatosis and Hepatitis C
Steatosis as a Modifier of Treatment Response
Clinical Management
Diagnosis: Measuring Insulin Resistance
Therapeutic Approaches
Weight loss
Drug Therapy
Pathogenesis
Insulin Resistance as a Cause of Fatty Liver
Hepatitis C as a Cause of Fatty Liver

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.